NewTimeSpace News: Carsgen Therapeutics Holdings Limited (02171.HK) announced that the New Drug Application for Kailimei® (Satricabtagene Autoleucel Injection), an in-house developed Claudin18.2-targeted CAR-T cell therapy product, has been granted marketing approval by the National Medical Products Administration (NMPA). It is indicated for the treatment of advanced gastric/gastroesophageal junction adenocarcinoma that is Claudin18.2-positive, HER2-negative and has failed at least two lines of prior therapy. Kailimei® is the world’s first CAR-T cell therapy product approved for solid tumor treatment.
NewTimeSpace News: Asiatic Group Holdings announced in a filing dated June 20 that its subsidiary has entered into a settlement agreement for the disposal of a 49% equity interest in Colben Energy (Cambodia) PPSEZ Limited, with a total consideration of US$3.1 million.
NewTimeSpace News: F J Benjamin Holdings Ltd announced via filing on June 22 that the company has entered placement agreements with two investors, proposing to place an aggregate of 42 million new ordinary shares at S$0.0072 per share for gross proceeds of around S$302,400.
NewTimeSpace News: June 18, 2026, GET NICE(00064.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 357.53 million, decreased by 17.26% YoY
NewTimeSpace News:June 18, 2026, ETERNAL BEAUTY(06883.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 2.15 billion, increased by 3.31% YoY
NewTimeSpace News: June 18, 2026, DAISHOMICROLINE(00567.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 43.43 million, decreased by 18.21% YoY
NewTimeSpace News: June 18, 2026, ELEPHANT HLDGS(08635.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 175 million, increased by 875.54% YoY
NewTimeSpace News: China Hongguang Holdings Limited (08646.HK) announced that Guangdong Longguang New Material Technology Co., Limited, its indirectly wholly-owned subsidiary, has officially expanded the new material business of TGV glass-based copper clad laminates. Its products cover AI computing packaging substrates, automotive-grade energy storage electronic base materials and other fields. The industrial chain has been established in Shenzhen in the first half of 2026, and a trial production line will be launched in the second half of the year.
NewTimeSpace News: First Pacific Co. Ltd. (00142.HK) announced that VITRO REIT under its principal operating associate PLDT Inc. has filed a registration statement and REIT scheme with the Securities and Exchange Commission of the Philippines, proposing an initial public offering on the Main Board of the Philippine Stock Exchange, which is expected to become the Philippines’ first digital infrastructure REIT. Assuming full exercise of the over-allotment option, the offer price is capped at PHP11.0 per share, with total gross proceeds projected to reach a maximum of PHP24.2 billion (approximately HK$3.1 billion).
NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained manufacturing registration approvals from the National Medical Products Administration (NMPA) for two pharmaceutical products. Safinamide Mesylate Tablets (100mg & 50mg), classified as Class 4 chemical drugs and deemed to have passed consistency evaluation, make SSY the third domestic pharmaceutical firm to secure approval for this product. Meanwhile, Procaterol Hydrochloride Inhalation Solution (0.3ml:30μg), a Class 3 chemical drug, also received registration approval with deemed consistency evaluation clearance.
NewTimeSpace (newtimespace.com) News: On June 22, 2026, the chip sector experienced a volatile trading trend. ASMPT (00522.HK) opened lower and fluctuated, with the company's share price quoted at HK$202.400, down 3.07% as of 13:25 PM.
NewTimeSpace News: Sihuan Pharmaceutical Holdings Group Ltd. (00460.HK) announced that the Phase III clinical study of self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) from its non-wholly-owned subsidiary Xuanzhu Biologics, evaluating bismuth quadruple therapy containing Anaprazole Sodium for Helicobacter pylori eradication, has completed the first patient dosing, marking the official launch of this pivotal registrational clinical trial.
NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Ltd. (02591.HK) announced that the Group obtained approval from the NMPA on 17 June 2026 to launch an Ib-stage clinical trial of Efsubaglutide Alfa for the treatment of adolescent obesity. The trial is scheduled to commence in July 2026, with a planned enrollment of approximately 36 participants.
NewTimeSpace News: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (03378.HK) announced that pursuant to FTSE Russell’s quarterly index review, the Company has been admitted to the FTSE Global Micro Cap Index under the FTSE Global Equity Index Series, with the inclusion effective after market close on 19 June 2026. The Board believes this inclusion broadly recognises the Company’s solid fundamentals, innovation capacity and growth potential from international capital markets, expected to lift its visibility among global institutional investors and analysts, attract inflows from passive and active funds tracking relevant indices, diversify shareholder base and enhance trading liquidity of its shares.
NewTimeSpace (newtimespace.com) News: On June 22, 2026, the robot concept sector fluctuated and weakened. Xiaomi Corporation-W (01810.HK) continued to open lower and move downward. As of 13:05 PM, the company's share price was quoted at HK$23.600, down 3.99%.
NewTimeSpace News: InSilico(03696.HK) announced a research and development collaboration with SK Biopharmaceuticals to discover AI-driven novel drug candidates targeting neuroimmune disorders of the central nervous system. Under the agreement, InSilico Medicine is eligible for upfront and near-term milestone payments of up to USD18 million, with the total potential deal value surpassing USD2.5 billion, covering development, regulatory and commercial milestones plus single-digit tiered royalties on net sales post-launch.
